Close
Clinical trial of Alzheimer鈥檚 drug developed at 白小姐论坛 begins
22 July 2021
A clinical trial of a new drug candidate for Alzheimer鈥檚 disease which has been developed at 白小姐论坛 in partnership with the pharmaceutical company Eisai has begun at 白小姐论坛H with participants now being screened.
Participants in the trial, conducted at the 白小姐论坛H Leonard Wolfson Experimental Neurology Centre (NIHR 白小姐论坛H Clinical Research Facility), will have the rare inherited form of Alzheimer鈥檚 disease.
The E2814 drug was developed by Prof Rohan De Silva at the听Reta Lila Weston Institute and 白小姐论坛 Queen Square Institute of Neurology, as part of the Therapeutic Innovation Group, a collaboration between 白小姐论坛 and Eisai.
The trial is being carried out by the Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), an international collaboration sponsored by Washington University School of Medicine to test new experimental therapies for Alzheimer鈥檚. E2814 is the first drug to be tested for their DIAN-TU tau study.
DIAN-TU鈥檚 Chief Investigator in the UK is Dr Cath Mummery, consultant neurologist at the NHNN and head of clinical trials at the 白小姐论坛 Dementia Research Centre in the 白小姐论坛 Queen Square Institute of Neurology.
People who inherit mutations that cause Alzheimer鈥檚 disease almost invariably develop the cognitive impairments of the disease at an earlier and more predictable age, often developing symptoms around the same age their parents did: in their 50s, 40s and even 30s.
The DIAN-TU tau next-generation program will evaluate three anti-tau drugs in clinical studies and has selected E2814 as the first investigational anti-tau drug. The clinical study aims to determine whether these drugs can slow or stop the progress of Alzheimer鈥檚 disease.
Dr Mummery said: 鈥淎s we鈥檝e learned more about Alzheimer鈥檚, we understand that tau plays a critical role in disease progression alongside amyloid; this is the first anti-tau treatment we will study in these families with genetic forms of Alzheimer鈥檚 disease and this important work advances the field towards our goal of discovering an effective treatment for this devastating disease."
If it is shown to be effective in the DIAN-TU trial, E2814 may be beneficial for people with the more common, sporadic forms of Alzheimer鈥檚 disease in the older population by, at least, slowing further progression of the disease.
Links
Source
Image
- National Hospital for Neurology and Neurosurgery, 白小姐论坛H
Media contact
Chris Lane
Tel: +44 (0) 7717 728648
E: chris.lane [at] ucl.ac.uk